$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000155905318000025 Filed on August 07, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$255.0K	$279.0K	$26.81M
YoY Change	16.44%	-98.96%	7951.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.240M	$10.99M	$10.91M
YoY Change	-25.72%	0.73%	34.19%
% of Gross Profit
Research & Development	$18.52M	$31.45M	$34.03M
YoY Change	-55.19%	-7.58%	5.17%
% of Gross Profit
Depreciation & Amortization	$800.0K	$800.0K	$800.0K
YoY Change	0.0%	0.0%	100.0%
% of Gross Profit
Operating Expenses	$24.58M	$63.35M	$44.94M
YoY Change	-54.28%	40.95%	10.99%
Operating Profit	-$24.32M	-$63.07M	-$18.13M
YoY Change	-54.57%	247.83%	-54.85%
Interest Expense	$790.0K	$830.0K	$20.00K
YoY Change	558.33%	4050.0%	-300.0%
% of Operating Profit
Other Income/Expense, Net	$726.0K	$1.241M	-$856.0K
YoY Change	-228.5%	-244.98%	791.67%
Pretax Income	-$23.60M	-$61.83M	-$18.99M
YoY Change	-56.38%	225.62%	-52.83%
Income Tax	$962.0K	-$1.946M	-$1.287M
% Of Pretax Income
Net Earnings	-$24.56M	-$59.88M	-$17.70M
YoY Change	-53.13%	238.3%	-56.23%
Net Earnings / Revenue	-9630.98%	-21463.08%	-66.02%
Basic Earnings Per Share	-$0.62	-$1.50	-$0.46
Diluted Earnings Per Share	-$0.62	-$1.50	-$0.46
COMMON SHARES
Basic Shares Outstanding	39.84M shares	39.82M shares	38.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$451.5M	$486.2M	$471.7M
YoY Change	-1.01%	3.07%	6.5%
Cash & Equivalents	$451.5M	$486.2M	$471.7M
Short-Term Investments
Other Short-Term Assets	$5.400M	$7.800M	$9.800M
YoY Change	-57.81%	-20.41%	34.25%
Inventory
Prepaid Expenses
Receivables	$0.00	$8.000K	$30.24M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$456.9M	$494.0M	$511.7M
YoY Change	-2.59%	-3.46%	13.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$52.95M	$53.40M	$55.84M
YoY Change	-4.39%	-4.38%	33.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$502.0K	$502.0K	$1.625M
YoY Change	-81.97%	-69.11%	-31.23%
Total Long-Term Assets	$67.72M	$69.26M	$67.28M
YoY Change	-1.31%	2.95%	29.47%
TOTAL ASSETS
Total Short-Term Assets	$456.9M	$494.0M	$511.7M
Total Long-Term Assets	$67.72M	$69.26M	$67.28M
Total Assets	$524.6M	$563.3M	$579.0M
YoY Change	-2.43%	-2.71%	15.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.485M	$10.05M	$12.55M
YoY Change	-59.46%	-19.87%	8.22%
Accrued Expenses	$10.00M	$14.10M	$25.00M
YoY Change	-61.54%	-43.6%	26.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.600M	$1.500M
YoY Change	300.0%
Total Short-Term Liabilities	$23.63M	$46.13M	$39.60M
YoY Change	-39.82%	16.5%	18.36%
LONG-TERM LIABILITIES
Long-Term Debt	$50.30M	$50.70M	$0.00
YoY Change
Other Long-Term Liabilities	$553.0K	$110.5M	$52.40M
YoY Change	-98.94%	110.88%	41487.3%
Total Long-Term Liabilities	$161.3M	$161.2M	$52.43M
YoY Change	209.29%	207.41%	37.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.63M	$46.13M	$39.60M
Total Long-Term Liabilities	$161.3M	$161.2M	$52.43M
Total Liabilities	$185.0M	$207.3M	$92.02M
YoY Change	102.32%	125.26%	28.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$575.5M	-$551.0M	-$342.2M
YoY Change	45.86%	61.01%	73.64%
Common Stock	$398.0K	$398.0K	$382.0K
YoY Change	3.65%	4.19%	11.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$339.7M	$356.0M	$487.0M
YoY Change
Total Liabilities & Shareholders Equity	$524.6M	$563.3M	$579.0M
YoY Change	-2.43%	-2.71%	15.21%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$24.56M	-$59.88M	-$17.70M
YoY Change	-53.13%	238.3%	-56.23%
Depreciation, Depletion And Amortization	$800.0K	$800.0K	$800.0K
YoY Change	0.0%	0.0%	100.0%
Cash From Operating Activities	-$33.57M	$58.13M	-$36.08M
YoY Change	89.23%	-261.11%	31.06%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$100.0K	-$210.0K
YoY Change	-72.22%	-52.38%	-70.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$10.00K
YoY Change		-100.0%	-100.25%
Cash From Investing Activities	-$150.0K	-$100.0K	-$210.0K
YoY Change	-72.22%	-52.38%	-95.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-970.0K	-860.0K	1.460M
YoY Change	-137.16%	-158.9%	48.98%
NET CHANGE
Cash From Operating Activities	-33.57M	58.13M	-36.08M
Cash From Investing Activities	-150.0K	-100.0K	-210.0K
Cash From Financing Activities	-970.0K	-860.0K	1.460M
Net Change In Cash	-34.69M	57.17M	-34.83M
YoY Change	121.38%	-264.14%	11.24%
FREE CASH FLOW
Cash From Operating Activities	-$33.57M	$58.13M	-$36.08M
Capital Expenditures	-$150.0K	-$100.0K	-$210.0K
Free Cash Flow	-$33.42M	$58.23M	-$35.87M
YoY Change	94.3%	-262.34%	33.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39836836	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
	dei	Trading Symbol TradingSymbol	PRTA
	prta	Accrued Offering Costs AccruedOfferingCosts	31000	USD
	prta	Accrued Offering Costs AccruedOfferingCosts	0	USD
CY2017Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	13509000	USD
CY2018Q2	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	10160000	USD
	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	1002000	USD
	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	1908000	USD
CY2017Q4	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51760000	USD
CY2018Q2	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51760000	USD
CY2017Q4	prta	Buildtosuit Lease Obligation Current BuildtosuitLeaseObligationCurrent	733000	USD
CY2018Q2	prta	Buildtosuit Lease Obligation Current BuildtosuitLeaseObligationCurrent	1474000	USD
CY2018Q2	prta	Buildtosuit Lease Obligation Currentand Noncurrent BuildtosuitLeaseObligationCurrentandNoncurrent	52165000	USD
CY2017Q4	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51515000	USD
CY2018Q2	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	50691000	USD
CY2018Q2	prta	Builtto Suit Leases At Cost BuilttoSuitLeasesAtCost	51800000	USD
CY2017Q2	prta	Collaboration Revenue CollaborationRevenue	26812000	USD
	prta	Collaboration Revenue CollaborationRevenue	27071000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1518000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1596000	USD
CY2018Q2	prta	Collaboration Revenue CollaborationRevenue	279000	USD
	prta	Collaboration Revenue CollaborationRevenue	506000	USD
CY2017Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2018Q2	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2017Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2018Q2	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2017Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2018Q2	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2018Q2	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0.0	shares
CY2017Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2018Q2	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2017Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2018Q2	prta	Deferred Shares Value DeferredSharesValue	0	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	1830000	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	1825000	USD
CY2018Q2	prta	Non Cash Restructuring Charges NonCashRestructuringCharges	2512000	USD
	prta	Non Cash Restructuring Charges NonCashRestructuringCharges	2512000	USD
	prta	Numberof Votes NumberofVotes	1	vote
CY2018Q2	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	845000	USD
CY2018Q2	prta	Purchaseand Contractual Obligation Due Remainderof Fiscal Year PurchaseandContractualObligationDueRemainderofFiscalYear	12671000	USD
CY2018Q2	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	90000	USD
CY2018Q2	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	105000	USD
CY2018Q2	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	5743000	USD
CY2018Q2	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	4661000	USD
CY2018Q2	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	24115000	USD
CY2018Q2	prta	Restructuring Reserve Due After Fifth Year RestructuringReserveDueAfterFifthYear	0	USD
CY2018Q2	prta	Restructuring Reserve Duein Fifth Year RestructuringReserveDueinFifthYear	0	USD
CY2018Q2	prta	Restructuring Reserve Duein Fourth Year RestructuringReserveDueinFourthYear	0	USD
CY2018Q2	prta	Restructuring Reserve Duein Second Year RestructuringReserveDueinSecondYear	5508000	USD
CY2018Q2	prta	Restructuring Reserve Duein Third Year RestructuringReserveDueinThirdYear	4556000	USD
CY2018Q2	prta	Restructuring Reserve Future Minimum Payments Due Remainderof Fiscal Year RestructuringReserveFutureMinimumPaymentsDueRemainderofFiscalYear	6510000	USD
CY2018Q2	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions	4869000	USD
CY2018Q2	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	2505501	shares
	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P5Y8M1D
CY2018Q2	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPeriodWeightedAverageExercisePrice	31.82
CY2017Q2	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	-1500000	USD
	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	-3400000	USD
CY2018Q2	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	16000	USD
	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	400000	USD
	prta	Sharebased Compensation Restructuring SharebasedCompensationRestructuring	0	USD
	prta	Sharebased Compensation Restructuring SharebasedCompensationRestructuring	2512000	USD
	prta	Sharebased Compensationnonrestructuring SharebasedCompensationnonrestructuring	12255000	USD
	prta	Sharebased Compensationnonrestructuring SharebasedCompensationnonrestructuring	13211000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13633000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	10052000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	240000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8000	USD
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	311000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	946000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	438000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	641000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7743000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9324000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	849154000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	906583000	USD
CY2017Q4	us-gaap	Assets Assets	496329000	USD
CY2018Q2	us-gaap	Assets Assets	563300000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	426327000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	494037000	USD
CY2017Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	70002000	USD
CY2018Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	69263000	USD
CY2017Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1316000	USD
CY2018Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1299000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	471729000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	417620000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	486212000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	390979000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	475785000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	421676000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	490268000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	84806000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	68592000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38482764	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39831836	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39831836	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38482764	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39831836	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39831836	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	385000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	398000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	157000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1198000	USD
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	49000	USD
CY2018Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	49000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	254000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	229000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2018Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	110242000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8113000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	11307000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	1500000	USD
CY2018Q2	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	1600000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.77
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7342000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3914000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y5M12D
CY2018Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	88400000	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	2096000	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-101000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10912000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21744000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10992000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25221000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18988000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-56033000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-61828000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-110608000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1287000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2948000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1946000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1983000	USD
CY2017	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-400000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	691000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	576000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4311000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-12222000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30062000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-232000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	110242000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8744000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2991000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	15884000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-346000	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	831000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1031000	USD
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	579000	USD
CY2018Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	579000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	89140000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	207294000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	496329000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	563300000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37371000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	46132000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	51769000	USD
CY2018Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	161162000	USD
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9078000	USD
CY2018Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9084000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	161334000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42323000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2607000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-280000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73921000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26549000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-17701000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53085000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-59882000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-108625000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	393000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-856000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1630000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1241000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1169000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	44944000	USD
	us-gaap	Operating Expenses OperatingExpenses	81474000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	63348000	USD
	us-gaap	Operating Expenses OperatingExpenses	112283000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18132000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54403000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-63069000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-111777000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1753000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	242000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	242000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	242000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	242000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	644000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	141000	USD
CY2017Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	200000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2018Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	200000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2843000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	502000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9185000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5104000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-874000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1284000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	410000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	138000	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1356000	USD
CY2018Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	500000	USD
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-1600000	USD
CY2018Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	2215000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	2215000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2712000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	280000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8467000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7817000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150323000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	39758000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	105000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12013000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4473000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62733000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62722000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54990000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53398000	USD
CY2018Q2	us-gaap	Purchase Obligation PurchaseObligation	5946000	USD
CY2018Q2	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2018Q2	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2018Q2	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2018Q2	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2018Q2	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2018Q2	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	5946000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34032000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59730000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31452000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66158000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2018Q2	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	20900000	USD
CY2018Q2	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	21600000	USD
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	18382000	USD
	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	283000	USD
	us-gaap	Restructuring Charges RestructuringCharges	18382000	USD
CY2017Q2	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2018Q2	us-gaap	Restructuring Costs RestructuringCosts	20904000	USD
	us-gaap	Restructuring Costs RestructuringCosts	20904000	USD
CY2018Q2	us-gaap	Restructuring Reserve RestructuringReserve	16574000	USD
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2018Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2018Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	18396000	USD
CY2018Q2	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	-283000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-442350000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-550975000	USD
CY2017Q2	us-gaap	Revenues Revenues	26812000	USD
	us-gaap	Revenues Revenues	27071000	USD
CY2018Q2	us-gaap	Revenues Revenues	279000	USD
	us-gaap	Revenues Revenues	506000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	6653000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12255000	USD
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	8821000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15723000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.722
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.728
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.839
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.794
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	559092	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	430000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1284800	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2953200	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	4046300	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	4046300	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.32
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.82
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30455000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4882000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4406752	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7719424	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.93
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.73
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4880000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7271257	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	28.99
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	25.63
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	49.80
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.39
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y7M6D
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y9M11D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	174536	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	407189000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	356006000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38073000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36922000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39824000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39257000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The receivable from Roche as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are amounts due from Roche entities located in the U.S. and Switzerland under the License Agreement that became effective January 22, 2014. Revenue recorded in the Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$52.8 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$54.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all pre-clinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-18-000025-index-headers.html	Edgar Link	pending
0001559053-18-000025-index.html	Edgar Link	pending
0001559053-18-000025.txt	Edgar Link	pending
0001559053-18-000025-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prta-20180630.xml	Edgar Link	completed
prta-20180630.xsd	Edgar Link	pending
prta-20180630_cal.xml	Edgar Link	unprocessable
prta-20180630_def.xml	Edgar Link	unprocessable
prta-20180630_lab.xml	Edgar Link	unprocessable
prta-20180630_pre.xml	Edgar Link	unprocessable
prta2018q210-q.htm	Edgar Link	pending
prta2018q210-qxex101separa.htm	Edgar Link	pending
prta2018q210-qxex102formof.htm	Edgar Link	pending
prta2018q210-qxex103formof.htm	Edgar Link	pending
prta2018q210-qxex311.htm	Edgar Link	pending
prta2018q210-qxex312.htm	Edgar Link	pending
prta2018q210-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2018 Q3 Form 10-Q Financial Statement

#000155905318000025 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2018 Q3 Form 10-Q Financial Statement

#000155905318000025 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta